Quick Facts: Stercia-5

• Therapeutic Domain 1: Management of symptoms associated with benign prostatic hyperplasia (BPH) in men with an enlarged prostate.
• Therapeutic Domain 2: May be used to assist in the improvement of hair count and to slow further hair loss in men with androgenetic alopecia (male pattern hair loss).

---

What Stercia-5 Treats: Main Uses and Benefits

Stercia-5 is a prescription medication used to address certain medical conditions in men. Its primary purpose is to help manage the symptoms of benign prostatic hyperplasia (BPH), which is commonly referred to as an enlarged prostate. For patients experiencing BPH, treatment with this medication may assist in improving related urinary symptoms and may lead to a reduction in prostate volume over time.

Separately, Stercia-5 may be utilized for men to help improve the appearance of androgenetic alopecia (male pattern hair loss). The medication may assist in stimulating hair growth and may help to slow the rate of hair loss in affected areas. Continued use is typically recommended to maintain the observed benefits.

Treatment decisions should always be made in consultation with a qualified healthcare provider.

Eligibility Map: Who Can and Cannot Use Stercia-5

Stercia-5 (Finasteride) is a prescription medicine with strictly defined population eligibility and contraindications based on regulatory documents.

---

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed	Adult Males (age ge 18 years) for its approved uses.
Populations for whom use is contraindicated	All women are strictly contraindicated, including women who are or may become pregnant.
Age-related eligibility rules	Contraindicated in children and adolescents ( age < 18 years). No dosage adjustment is necessary for older adults.
Condition-specific eligibility rules	Use requires caution in patients with liver function abnormalities. No dosage adjustment is required for patients with renal impairment.
Eligibility-related restrictions	Patients must be evaluated to rule out prostate cancer before initiating treatment for Benign Prostatic Hyperplasia (BPH).

---

Eligibility Classifications (High-Level)

Classification Detail	Regulatory Statement
Eligibility severity classification	Contraindicated (absolute prohibition) in women, pregnancy, and children; Caution required for hepatic impairment.
Eligibility-context constraints	Women who are or may be pregnant must not handle crushed or broken tablets due to the risk of absorption and potential harm to a male fetus.

Connection to the overall eligibility profile: Regulatory documents strictly define the eligible user base as adult males and establish absolute prohibitions against use by all females and pediatric patients. This profile also mandates pre-treatment evaluation for BPH to exclude other urological conditions.

Interactions with other medicines and products

Official regulatory information regarding Stercia-5 (Finasteride) establishes a profile characterized by the absence of clinically important interactions with commonly co-administered medicinal products. The following summary reflects the conclusions documented in government regulatory sources.

Documented Interaction Profile

Classification	Official Regulatory Statement
Interaction Severity	Absence of clinically important interactions is the regulatory finding with tested agents.
Contraindications	None are formally listed in official labeling concerning co-administration with other medicines.
Food Interaction	May be taken with or without food, as no clinically significant drug–food interaction is documented.

Pharmacokinetic and Exposure Findings

Finasteride is primarily metabolized in the liver via the CYP450 3A4 enzyme; however, official studies demonstrate that the active substance does not appear to affect the Cytochrome P450-linked drug-metabolizing enzyme system. This conclusion minimizes the potential for metabolic drug–drug interactions.

Specific co-administration studies with Digoxin, Propranolol, Theophylline, and Warfarin resulted in no clinically meaningful changes in drug exposure (e.g., AUC or Cmax) or effect. Consequently, regulatory documents do not specify any mandatory time-separation requirements for co-administration. Although metabolite plasma concentrations are increased in patients with renal impairment, this finding is not associated with an interaction requiring a dose or regimen modification.

How Stercia-5 Works: The Mechanistic Domains

Stercia-5's mechanism is fundamentally based on modulating the hormonal cascade through enzyme inhibition in androgen-sensitive tissues. The drug acts as a specific competitive inhibitor that binds predominantly to the Type 2 5-alpha reductase enzyme . This action blocks the function of converting Testosterone into the more potent androgen, Dihydrotestosterone (DHT), thereby modulating the body's androgen metabolism pathway.

By continually suppressing the enzyme, the drug achieves a sustained decrease in systemic DHT concentration (approximately 70%). This reduced availability lowers the hormonal stimulus acting on the Nuclear Androgen Receptor in specific cells, resulting in a diminished signal for cellular proliferation. This molecular cascade leads to the gradual regression and alteration of growth patterns in androgen-dependent structures, a time-dependent physiological consequence. The mechanism is inherently constrained by the drug's lower efficacy against the remaining Type 1 5-alpha reductase isozyme.

How to Use Stercia-5

The administration of Stercia-5 is governed by protocols that define the precise dose strength and frequency required for each scenario. The medication is delivered exclusively via the oral route as a film-coated tablet, designed for systemic action.

Official Dosing and Frequency

The dose is determined by the specific usage pattern. For benign prostatic hyperplasia (BPH), the standard regimen is a 5 mg tablet administered once daily. When utilized for androgenetic alopecia (male pattern hair loss), the standard regimen is a 1 mg tablet administered once daily. In both instances, the required pattern is a consistent, single dose per day (qDay).

Administration and Procedural Rules

Stercia-5 tablets may be taken with or without food; however, to maintain the integrity of the formulation, the tablet must be swallowed whole and is directed not to be divided or crushed. If a dose is missed, it is recommended to skip the missed dose entirely and resume the regimen at the next scheduled time, without taking a double dose.

Usage Duration and Special Populations

The established protocol for both uses necessitates long-term, continuous daily administration to maintain the therapeutic effect. A minimum of three to six months of daily use is typically required before the effectiveness of the regimen can be assessed. Standard instructions state that no dosage adjustment is required for older adults or patients with renal impairment. The medicine is not indicated for use in the pediatric population.

Evidence for use in Benign Prostatic Hyperplasia (BPH)

Research for Stercia-5 in BPH was primarily conducted through Randomized Controlled Trials (RCTs) and systematic reviews. These studies examined changes in urinary symptom scores, prostate volume, and maximum urinary flow rate. Long-term studies tracked key BPH-related events, such as the need for surgery or acute urinary retention. Findings suggest that the documentation of these patterns was more frequent among men who presented with a larger baseline prostate volume at the start of the study.

---

Evidence for use in Androgenetic Alopecia (Male Pattern Hair Loss)

The evidence base for male pattern hair loss is derived from RCTs and long-term extension studies focused on adult men experiencing hair loss on the vertex (crown) and mid-scalp. Researchers monitored several outcomes related to appearance, primarily through the direct counting of scalp hair in defined target areas and patient self-assessments. Research describes patterns showing that measured changes were maintained only within the study periods when the compound was used.

---

Research Gaps and Specific Populations

The research evidence provides limited insight into the clinical course for men with BPH but a smaller prostate volume. Furthermore, the evidence base for hair loss did not establish changes in the receding hairline (bitemporal) area. The research indicates that data for certain groups, such as the older adult male population or those with rapidly progressing hair loss, remain insufficient for full characterization. Data for long-term outcomes extending significantly beyond four to six years are not fully established.

Common questions about Stercia-5 (FAQ)

---

Q: How long will it take before I see results for hair loss?

Studies and official product information indicate that for treating male pattern hair loss, it may take at least 3 months to see an initial effect. Results may be observed over a period of up to 12 months of continuous use. Official product information notes that any potential effects on hair growth are typically maintained only while the medicine is being used.

---

Q: How long does Stercia-5 stay in my system after I stop taking it?

The elimination half-life, which is the time it takes for the body to clear half the medicine, is reported to be approximately 5 to 8 hours. However, the body's levels of the hormone it affects, DHT, typically return to their pretreatment levels within about 14 days after discontinuation of the medicine.

---

Q: What type of cancer does Stercia-5 increase the risk for?

Official regulatory warnings note an observed increase in the risk of developing a high-grade prostate cancer (a type of more serious cancer) in men aged 55 and over taking the 5 mg dose. This information is documented in the warnings section of the official regulatory label.

---

Q: Can this drug help my receding hairline?

Official product information indicates that studies for hair loss focused on the vertex (crown) and mid-scalp. Effectiveness for the receding hairline (bitemporal area) has not been established in the clinical data used for approval.

---

Q: What are the special handling instructions for Stercia-5?

Due to the potential for absorption through the skin, women who are or may become pregnant must not handle crushed or broken tablets. This is a safety precaution against potential risk to a male fetus. The film-coated tablets are considered safe to handle when intact.

---

Q: Does Stercia-5 affect my cholesterol or blood sugar levels?

Clinical trial data reviewed by regulatory authorities do not list changes to common metabolic values, such as cholesterol or blood sugar (glucose) levels, as a documented common or uncommon adverse reaction.

---

Q: Will Stercia-5 cause me to gain or lose weight?

Official regulatory documents and the corresponding clinical trial data do not list either weight gain or weight loss as a documented common or uncommon adverse reaction associated with this medication.

---

Q: What is the recommended method for disposing of unused or expired Stercia-5 tablets?

Official instructions indicate that unused or expired Stercia-5 should be disposed of by utilizing a drug take-back program or a community collection site if one is available. Regulatory guidelines advise against disposing of the tablets by flushing them down the toilet or putting them in the household rubbish, as this helps protect the environment.

Storing and Disposing of Finasteride 5 mg Tablets: Official Requirements

Finasteride 5 mg tablets (similar to Stercia-5) do not require special storage conditions, allowing for storage at room temperature.

Required Storage and Handling

Requirement	Official Statement (Regulatory Basis)
Child Safety	The medicine must be kept out of the sight and reach of children (Mandatory).
Special Handling	Pregnant women must not handle crushed or broken tablets due to the potential for finasteride absorption. The film coating prevents contact with the active ingredient.
General Conditions	Store in the original container under standard ambient conditions.

Official Disposal Rules

Any unused or expired product must be disposed of in accordance with local requirements. Regulatory guidelines prohibit disposal via wastewater or general household rubbish to protect the environment. Disposal should follow established local pharmaceutical collection or household disposal programs.